Literature DB >> 31828733

Pre-exposure Prophylaxis Therapy and the Blood-Brain Barrier: Is PrEP Neuroprotective?

Joanna Kettlewell1, Maya Barney2, Robert Oda3, Melissa Agsalda-Garcia1, Chathura Siriwardhana4, Bruce Shiramizu5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31828733      PMCID： PMC7141950          DOI： 10.1007/s11481-019-09898-3

Source DB:  PubMed          Journal:  J Neuroimmune Pharmacol        ISSN： 1557-1890            Impact factor:   4.147


× No keyword cloud information.
  9 in total

1.  Lack of prophylactic efficacy of oral maraviroc in macaques despite high drug concentrations in rectal tissues.

Authors:  Ivana Massud; Wutyi Aung; Amy Martin; Shanon Bachman; James Mitchell; Rachael Aubert; Theodros Solomon Tsegaye; Ellen Kersh; Chou-Pong Pau; Walid Heneine; J Gerardo García-Lerma
Journal:  J Virol       Date:  2013-06-05       Impact factor: 5.103

2.  Central nervous system viral invasion and inflammation during acute HIV infection.

Authors:  Victor Valcour; Thep Chalermchai; Napapon Sailasuta; Mary Marovich; Sukalaya Lerdlum; Duanghathai Suttichom; Nijasri C Suwanwela; Linda Jagodzinski; Nelson Michael; Serena Spudich; Frits van Griensven; Mark de Souza; Jerome Kim; Jintanat Ananworanich
Journal:  J Infect Dis       Date:  2012-05-02       Impact factor: 5.226

3.  Improved Cognitive Performance and Reduced Monocyte Activation in Virally Suppressed Chronic HIV After Dual CCR2 and CCR5 Antagonism.

Authors:  Michelle L DʼAntoni; Robert H Paul; Brooks I Mitchell; Lindsay Kohorn; Laurent Fischer; Eric Lefebvre; Star Seyedkazemi; Beau K Nakamoto; Maegen Walker; Kalpana J Kallianpur; Debra Ogata-Arakaki; Lishomwa C Ndhlovu; Cecilia Shikuma
Journal:  J Acquir Immune Defic Syndr       Date:  2018-09-01       Impact factor: 3.731

Review 4.  Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders.

Authors:  Melanie D Sweeney; Abhay P Sagare; Berislav V Zlokovic
Journal:  Nat Rev Neurol       Date:  2018-01-29       Impact factor: 42.937

5.  HIV pre-exposure prophylaxis: mucosal tissue drug distribution of RT inhibitor Tenofovir and entry inhibitor Maraviroc in a humanized mouse model.

Authors:  Milena Veselinovic; Kuo-Hsiung Yang; Jonathan LeCureux; Craig Sykes; Leila Remling-Mulder; Angela D M Kashuba; Ramesh Akkina
Journal:  Virology       Date:  2014-08-07       Impact factor: 3.616

6.  Treatment intensification with maraviroc (CCR5 antagonist) leads to declines in CD16-expressing monocytes in cART-suppressed chronic HIV-infected subjects and is associated with improvements in neurocognitive test performance: implications for HIV-associated neurocognitive disease (HAND).

Authors:  Lishomwa C Ndhlovu; Tracie Umaki; Glen M Chew; Dominic C Chow; Melissa Agsalda; Kalpana J Kallianpur; Robert Paul; Guangxiang Zhang; Erika Ho; Nancy Hanks; Beau Nakamoto; Bruce T Shiramizu; Cecilia M Shikuma
Journal:  J Neurovirol       Date:  2014-09-17       Impact factor: 2.643

7.  Maraviroc-intensified combined antiretroviral therapy improves cognition in virally suppressed HIV-associated neurocognitive disorder.

Authors:  Thomas M Gates; Lucette A Cysique; Krista J Siefried; Joga Chaganti; Kirsten J Moffat; Bruce J Brew
Journal:  AIDS       Date:  2016-02-20       Impact factor: 4.177

8.  Phase 2 Study of the Safety and Tolerability of Maraviroc-Containing Regimens to Prevent HIV Infection in Men Who Have Sex With Men (HPTN 069/ACTG A5305).

Authors:  Roy M Gulick; Timothy J Wilkin; Ying Q Chen; Raphael J Landovitz; K Rivet Amico; Alicia M Young; Paul Richardson; Mark A Marzinke; Craig W Hendrix; Susan H Eshleman; Ian McGowan; Leslie M Cottle; Adriana Andrade; Cheryl Marcus; Karin L Klingman; Wairimu Chege; Alex R Rinehart; James F Rooney; Philip Andrew; Robert A Salata; Manya Magnus; Jason E Farley; Albert Liu; Ian Frank; Ken Ho; Jorge Santana; Joanne D Stekler; Marybeth McCauley; Kenneth H Mayer
Journal:  J Infect Dis       Date:  2017-01-15       Impact factor: 5.226

9.  Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.

Authors:  C Preston Neff; Thomas Ndolo; Apurva Tandon; Yuichiro Habu; Ramesh Akkina
Journal:  PLoS One       Date:  2010-12-21       Impact factor: 3.240
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.